Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

Annals of the Rheumatic Diseases

Volumn 55, Issue 4, 1996, Pages 218-223

  Van Der Veen, M J ^a   Dinant, H J ^b   Van Booma Frankfort, C ^c   Van Albada Kuipers, G A ^d   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

^d EEMLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHOTREXATE; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC POLYMYALGIA; SIDE EFFECT; WEIGHT GAIN;

EID: 0029914589     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.4.218     Document Type: Article

References (22)

1. Hellmann D B. Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis. Curr Opin Rheumatol 1993; 5: 25-32.
2. Healey L A. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322-8.
3. Bengtsson B-A, Malmvall B-E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209: 337-45.
4. Kyle V, Hazleman B L. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 847-50.
5. Fernandez-Herlihy L. Temporal arteritis: clinical aids to diagnosis. J Rheumatol 1988; 15: 1797-801.
6. Behn A R, Perera T, Myles A B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8.
7. Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. J Rheumatol 1980; 7: 361-4.
8. Ayoub W T, Franklin C M, Toretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985; 79: 309-15.
9. Chuang T-Y, Hunder G G, Ilstrup D M, Kurland L T. Polymyalgia rheumatica. A 10-year epidemiologic and clinical study. Ann Int Med 1982; 97: 672-80.
10. Huston K A, Hunder G G. Giant cell (cranial) arteritis: a clinical review. Am Heart J 1980; 100: 99-107.
11. Healey L A, Wilske K R. Treatment of resistant giant cell arteritis. Arthritis Rheum 1983; 26: 930.
12. Kyle V, Hazleman B L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. Treatment usually lasts for two to five years. BMJ 1990; 300: 344-5.
13. Kyle V, Hazleman B L. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.
14. Shiner R J, Nunn A J, Fan Chung K, Geddes D M. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.
15. Hoffman G S, Leavitt R Y, Kerr G S, Rottem M, Sneller M C, Fauci A S. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.
16. Hernández-García C, Soriano C, Morado C, et al. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol 1994; 23: 295-8.
17. Hunder G G, Bloch D A, Michel B A, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
18. Goldsmith C H, Smythe H A, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993; 20: 575-8.
19. Krall P L, Mazanec D J, Wilke W S. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1989; 56: 253-7.
20. Bengtsson B-A, Malmvall B-E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.
21. Myles A B, Perera T, Ridley M G. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31: 103-5.
22. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi J B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9.